
Opinion|Videos|March 13, 2025
RATIONALE-305: Exploring Adverse Event Profile
Panelists discuss how the RATIONALE-305 trial revealed a manageable adverse event profile for tislelizumab plus chemotherapy despite increased rates of neutropenia and anemia compared to placebo plus chemotherapy in advanced gastric cancer patients.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Speed Is the Story: How Sequencing the Human Genome Transformed Cancer Care
2
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
3
Lung Cancer News Roundup: June 2026
4
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
5









































